Table VIII.

Summary of four risk-prediction models for survival or amputation-free survival (AFS) after revascularization^a

Study	VSGNE PVI	BASIL	PREVENT III	FINNVASC
Revascularization	PVI (n = 1253)	PVI (n = 228) or LEB (n =224)	LEB (n = 1404)	LEB (n = 3925)
Outcome	1-year AFS	2-year AFS	1-year AFS	30-day AFS
Variable
Renal insufficiencyb	1.9–3.8	2.0	2.8
Agec	2.2	1.7	1.6
Emergency procedure	2.5			1.8
Not living at home	2.0
CHF	1.7
Chronic β-blockers	1.4
Independent ambulation	0.7
Tissue lossd		2.6	2.2	1.5
CAD		↓	1.4	1.4
Diabetes, type 1 or 2		1.2		1.5
Bollinger score below knee 5–8		1.9
Smoking		1.7
BMI <20 kg/m2		1.5
Stroke/TIA		↓
Ankle pressurese		↓
Hematocrit <30			1.6
Model discrimination: reported C index validation8–12	0.74	–	–	0.60
	Not validated	0.65–0.70	0.58–0.63	0.50–0.58

BASIL, Bypass versus Angioplasty in Severe Ischaemia of the Leg; BMI, body mass index; CAD, coronary artery disease; CHF, congestive heart failure; CLI, critical limb ischemia; FINNVASC, Finland National Vascular prediction model; LEB, lower extremity bypass; PREVENT III, Edifoligide for the Prevention of Infrainguinal Vein Graft Failure; PVI, peripheral vascular intervention; TIA, transient ischemic attack; VSGNE, Vascular Study Group of New England.

^aHazard ratios (HRs) or odds ratios (ORs) from original publication. ↓ indicates decreased overall survival (OS) or amputation free survival (AFS) when HR not reported.

^bCreatinine ≥1.78 mg/dL or dialysis for VSGNE, creatinine >4.7 mmol/L for BASIL, on dialysis for PREVENT III.

^cAge >80 years for VSGNE PVI and BASIL, >75 years for PREVENT III.

^dDefined as any tissue loss for PREVENT III and BASIL (with ankle pressure <50 mm Hg) and gangrene for FINNVASC.

^eIncludes number of serial ankle pressures obtained and maximum pressure.